Get to Know CTRC


Do you know what CTRC does?

Patient care is our number one priority at the CTRC and we look forward to assisting you in any way we can -- whether it's simply with information or perhaps a second opinion on treatment for yourself or a family member. CTRC's total patient care system consists of break-through research, state-of-the-art tools and technology and multidisciplinary clinical care delivered through a team of world-class physicians, laboratory scientists and other medical professionals. This system allows it to seamlessly translate the latest research findings more efficiently and directly to patients. We also conduct research and clinical trials, teaming with the National Cancer Institute, the National Institutes of Health and other universities to discover new cures and treatments for cancer.

Do you know what our CTRC physicians do?

CTRC has some of the world's leading experts in different types of cancer, as well as an integrated, multi-disciplinary care team that means more physicians, technicians and specialists are working together to look at each and every case, making sure it is the optimal treatment plan. We treat the cancer, and care for the patient. Our scientists and doctors are committed to conquering cancer one patient at a time.

Do you know what your support of CTRC means?

With one in three Americans touched by cancer, the quest to eliminate this disease as a cause of human suffering and death requires help in many forms. Your gifts provide someone facing cancer with hope for the future - time - the most precious gift in the world. As an academic cancer center, the CTRC is not only conducts research and trains the physicians of tomorrow through the UT School of Medicine, but also sees patients of every income level.

Do you know what an NCI designation for CTRC means?

Any center can call itself a cancer center, but only a very few centers receive the National Cancer Institute (NCI) designation. These centers are scrutinized, tested and audited by the NCI and found to offer a comprehensive approach to all aspects of the disease, including novel and improved ways to diagnose, prevent and treat cancer. There are only 67 NCI-designated Cancer Centers in the United States and only four in Texas. The CTRC is the only NCI-designated Cancer Center in San Antonio and South Texas. In an NCI-designated Cancer Center, teams of scientists work with clinicians to translate laboratory discoveries into practical application, including more effective ways to diagnose, prevent and treat all types of cancers. The close association with the NCI allows these centers access to information and discoveries through the NCI, and access to its pipeline of exciting new treatment possibilities.

Do you know about clinical trials at the CTRC?

CTRC doctors lead a wide range of clinical trials, including Phase I trials, which are often the first clinical studies for new medications. The conduct of clinical studies is a major responsibility that is carefully regulated at multiple levels; locally by our institutional committees and nationally by the U.S. Food and Drug Administration. Our doctors and research personnel explain in great detail all that is involved in each trial, including procedures and treatment plan, and the potential risks and benefits; they also serve as your advocate. As our patient, you have the right to choose your treatment after a thorough discussion with your health care providers. We work very hard to ensure that there are available clinical trial options for your type of disease; it is our goal to make breakthrough innovations that will make lives better.

Do you know about drug development at CTRC?

The mission of the CTRC's Institute for Drug Development (IDD) is to develop new and more effective treatments for patients with cancer through integration of research programs of excellence in the translational and clinical sciences. The IDD has set unprecedented standards for the development of anti-cancer agents, playing a key role in the preclinical and clinical development of 20 new cancer drugs that were subsequently approved by the U.S. Food and Drug Administration.